Member Info for stephen11

Thanks john - wasn't aware of the delay.

All eyes will be on GDR, but remember this:

In May 2020, as some have previously reported the SP hit £2.00, although at this time there were a mere 67 million shares on offer.

If you compare that with today, there are now 543.14 million shares. No chance of this rising to these dizzy heights with the extra shares on offer.

So, where might the SP go?

Realistically, after good news on the 17th from NHS Scotland, and hopefully concrete sales, between 7p to 10p is possible.

For 10p to 15p we would need word of sales from Europe and further afield or news on an FDA submission.

Encouraging signs today though 😊.

GLA.

Stephen11.

I thought the 17th Oct was mentioned previously for the publication by the Scottish Health technologies group?

Something must have lit 🔥 this flame 🔥

RNS must be imminent.

Could hit +50% today

Maybe in about 2 years Basil, but not overnight for 50p. We’d need FDA and American sales - Hope it happens though!

That would be an Mcap of £250 million.

A £50 million Mcap and an sp between 7p to 20p is more realistic in the near term.

GLA.

Stephen11.

Wadogara - GDR raised money in May 2024 and it came through in June 2024.

6 million raised and the monthly cash burn is between £400,000 to £450,000 per month.

We’re good until around June to September 2025.

Stephen11.

And it’s only 12.20 🤣

In May 2020, as some have previously reported the SP hit £2.00, although at this time there were a mere 67 million shares on offer.

If you compare that with today, there are now 543.14 million shares. No chance of this rising to these dizzy heights with the extra shares on offer.

So, where might the SP go?

Realistically, after good news on the 17th from NHS Scotland, and hopefully concrete sales, between 7p to 10p is possible.

For 10p to 15p we would need word of sales from Europe and further afield or news on an FDA submission.

Encouraging signs today though 😊.

GLA.

Stephen11.

With one very important caveat!

So, mainly in anticipation of NICE publication, this share moved from 1.75p to 4.5p between the 8th and 17th of July.

This time we appear to be moving up in anticipation of the NHS Scotland guidance document, due to be published on the 17th Oct.

However, if we get a monetary value attached to any orders or future usage information things could get very interesting. A percentage increase off a 5p starting SP could be on the cards. The difference is NICE did not give orders or usage figures, just potential - I hope NHS Scotland put meat on the bone.

The wise investors are taking positions.

Enough said.

GLA.

Stephen11.

09-Oct-24 14:07:57 2.02 74,257 Buy* 1.95 2.05 1,500 O

09-Oct-24 14:04:53 2.02 73,665 Buy* 1.95 2.05 1,488 O

09-Oct-24 14:03:00 2.02 45,619 Buy* 1.95 2.05 921.50 O

09-Oct-24 13:47:40 2.02 100,000 Buy* 1.95 2.05 2,020 O

09-Oct-24 13:47:09 2.02 100,000 Buy* 1.95 2.05 2,020 O

09-Oct-24 13:46:54 2.00 50,000 Buy* 1.90 2.00 1,000 O

09-Oct-24 13:46:45 1.99 500,000 Buy* 1.90 2.00 9,950 O

09-Oct-24 13:44:14 1.999 2,001 Buy* 1.90 2.00 40.00 O

09-Oct-24 13:44:14 1.99 50,000 Buy* 1.90 2.00 995.00 O

09-Oct-24 13:44:09 1.99 500,000 Buy* 1.90 2.00 9,950 O

09-Oct-24 13:43:28 1.999 100 Buy* 1.90 2.00 2.00 O

09-Oct-24 13:40:46 1.9995 100,000 Buy* 1.95 2.00 2,000 O

09-Oct-24 13:39:11 1.9767 161,641 Sell* 1.95 2.05 3,195 O

Https://www.england.nhs.uk/digitaltechnology/

I attach some info on the NHS vision to have a fully automated, paper loss workplace (America call this the Digital Hospital and done this years ago). I know many trusts have implemented this. Patient information can be imputed electronically and then be accessed immediately by health professionals across the hospital departments to aid speed of treatment.

Eg., A consultant could view an X-ray result or a blood result seconds after it had been inputted into the system and make speedy treatment decisions.

What would you prefer if you had a stroke:

A/ You get a blood test taken that will be back in 2-5 days at best - your treatment depends on the result of this test, so you are in limbo at this critical time, when you are at heightened risk of secondary stroke.

Or.,

B/ you get the GDR swab test, it’s back in an hour and you then receive Clopidogrel or a more appropriate medication.

Should common sense not prevail here!? Could this be any simpler?

GLA.

Stephen11

---CYP2C19 - ID Kit---

- JC states at the last presentation that there is no reason why the CYP2C19 test will not get full recommendation in July....AND HE WAS RIGHT!!!!

- The world market is worth over £200m per annum

- UK Market £8.5m/ EU £93.5m/ US £67.5m/ RoW £51m

- CE-IVD marking in application process to open the European market

- Some interested parties want to use the CYP2C19 test on a research only basis around Europe

- Stroke incidence on the increase around the UK and predicted to increase by 60% between 2015 and 2035 (due to obesity and ageing population)

- The turnaround time for the labs is 2 days at the earliest - NICE says the test is time critical and must be done much earlier, as stroke patients are at risk off another stroke at this time

---MTRNR-1 AHIL (Antibiotic Induced Hearing Loss) ---

- Approximately 100 thousand UK neo-natal admissions per year (GDRs potential market)

- Market valued at +£100m worldwide

- UK 8.5m/ EU £46m/ US £34m/ RoW £13.75m

- Already has the CE-IVD cert to sell in EU, Europe, and the world

- EVA evidence generation in place to help achieve full NICE accreditation

- Specialist commissioning is scheduled for April 2025 - though GDR are campaigning for this to happen sooner

£5m cash in the bank and a revenue of at least £8.5m a year starting in 2024/2025

An MCAP of £11.00m - massively undervalued when you consider that GDR are on the cusp of real commercial traction.

GLA.

Stephen11.

I've been here for four years and reviewed every RNS, company update, and daily share movement, along with any other info i deemed important.

Both painful and happy moments, but here's what i've learnt about this share:

1/ Its a feel good news story and will get a fair degree of TV and newspaper coverage over the coming weeks and months

2/ Private institutions have always shied away from this share due to lack of commercial traction. This will change now that we have a clear route to market with the NHS

3/ Don't assume all longtermholders will sell. Some may have very different averages....5p, 10p, 15p, 50p...i know one shareholder (Punit) with an average of over £2.00. Sell off with be in stages

4/ The NICE accreditation is an extremely stringent process. Make no mistake....the Middle East and there private healthcare system will now have the green light to adopt the stroke ADR test

5/ When this share moves, she goes fast like a speedboat....expect fireworks

GLA.

Stephen11.

Mostly from Dr John Mcdermott of the University of Manchester:

https://research.manchester.ac.uk/en/publications/public-preferences-for-pharmacogenetic-testing-in-the-nhs-embeddi

https://research.manchester.ac.uk/en/publications/understanding-general-practitioner-and-pharmacist-preferences-for

https://research.manchester.ac.uk/en/publications/development-of-a-point-of-care-genetic-test-for-effective-treatme

https://research.manchester.ac.uk/en/publications/pharmacogenetics-clinical-decision-support-tools-for-primary-care

https://research.manchester.ac.uk/en/publications/characterizing-pharmacogenetic-programs-using-the-consolidated-fr

https://research.manchester.ac.uk/en/publications/rapid-point-of-care-genotyping-to-avoid-aminoglycoside-induced-ot

https://research.manchester.ac.uk/en/publications/the-role-of-cyp2c19-genotyping-to-guide-antiplatelet-therapy-foll

https://research.manchester.ac.uk/en/publications/pharmacogenomic-testing-to-support-prescribing-in-primary-care-a-

https://research.manchester.ac.uk/en/publications/the-pharmacogenetics-to-avoid-loss-of-hearing-paloh-trial-a-proto

You'd think that this would be more than enough info for any country or public/private health care trust who are sitting on the fence before purchasing GDRs tests.

GLA.

Stephen11.

Indeed - up 22%

Lots of lovely blue buys coming in anyways!

That old tea lady has been talking over the chocolate digestives again BigBench - we'll all seen this before with GDR.

And the buy is on 2.15p on Hargreaves Lansdown.

It's a start.

Something is definitely brewing - i'm hoping this big pilot/scoping study with regards to the NICE CYP2C19 stroke assay will getting officially announced soon - we're always the last to know!

GLA.

Stephen11.

Great share Mrg - more info about the National NICE pilot for the stroke assay is imminent according to the video i.e., this week on next from the time of the upload.